» Articles » PMID: 16950752

Changes in Prothrombin and Activated Partial Thromboplastin Time During Replacement Therapy with Human Recombinant Growth Hormone in Growth Hormone Deficient Adults

Overview
Specialty Endocrinology
Date 2006 Sep 5
PMID 16950752
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In rodents, Growth Hormone (GH) has been shown to stimulate coagulation parameters, including Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT) and vitamin K dependent coagulation factors. However, there are no reports on the influence of GH replacement therapy on global coagulation tests in Growth Hormone Deficiency (GHD).

Objective: The aim of this study was to investigate the effects of GH administration on basic coagulation parameters: PT, aPTT and fibrinogen concentrations in adult GHD patients before and during one year of GH replacement.

Design: Twenty-one adult patients with severe GHD (mean age +/- SE: 38.6 +/- 2.8 years) were included in this hospital based, prospective, interventional study. All patients were treated with rhGH for 12 months (GH dose: 0.4 mg/day for male and 0.6 mg/day for female patients). IGF-1 concentrations were determined using RIA-INEP kits. Basic coagulation tests, i.e. aPTT and fibrinogen concentrations, were measured before and after 3, 6 and 12 months of treatment with rhGH. Control values were obtained from fourteen "healthy" subjects matched by age, sex and body mass index (BMI).

Results: At baseline, we observed no significant differences in PT, aPTT and fibrinogen values between GHD and healthy subjects. IGF-1 concentrations increased significantly within 3 months of GH therapy (8.2 +/- 1.5 vs. 24.2 +/- 2.9 nmol/l, p <0.05) and remained stable thereafter. A significant increase in PT values, which was more pronounced in female subjects, was noted after 6 and 12 months of treatment with GH. aPTT values increased significantly after 12 months of treatment only in male patients (28.8 +/- 4.6 vs. 39.7 +/- 2.1 s.; p <0.05). No significant changes in fibrinogen concentrations were found during the study.

Conclusions: Twelve months of GH replacement therapy led to a significant increase in PT and aPTT values in adult GHD patients, while fibrinogen concentrations did not change. Changes in PT were more pronounced in female GHD patients, while an increase in aPTT values was observed only in male patients with GHD. The clinical significance of these changes needs further evaluation.

Citing Articles

Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.

Pezzino S, Luca T, Castorina M, Puleo S, Latteri S, Castorina S Life (Basel). 2024; 14(1).

PMID: 38255708 PMC: 10820028. DOI: 10.3390/life14010093.


Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile.

Ratku B, Sebestyen V, Erdei A, Nagy E, Szabo Z, Somodi S Pituitary. 2022; 25(2):211-228.

PMID: 35106704 PMC: 8894188. DOI: 10.1007/s11102-022-01207-1.


Role of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy.

Yalcin A, Topuz M, Biyik I, Akturk I, Celik O, Isiksacan N Postepy Kardiol Interwencyjnej. 2014; 10(4):242-9.

PMID: 25489317 PMC: 4252321. DOI: 10.5114/pwki.2014.46765.


Unusual effects of GH deficiency in adults: a review about the effects of GH on skin, sleep, and coagulation.

Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F Endocrine. 2014; 47(3):679-89.

PMID: 24816469 DOI: 10.1007/s12020-014-0276-0.


Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns.

Wong J, Dukes J, Levy R, Sos B, Mason S, Fong T J Clin Invest. 2008; 118(8):2969-78.

PMID: 18618017 PMC: 2447928. DOI: 10.1172/JCI34957.